Cargando…

Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer

The purpose was to investigate the interrater agreement of FDG-PET/CT and bone scintigraphy for diagnosing bone recurrence in breast cancer patients. A total of 100 women with suspected recurrence of breast cancer underwent planar whole-body bone scintigraphy with [99mTc]DPD and FDG-PET/CT. Scans we...

Descripción completa

Detalles Bibliográficos
Autores principales: Holm, Jorun, Ahangarani Farahani, Ziba, Gerke, Oke, Baun, Christina, Falch, Kirsten, Malene Grubbe, Hildebrandt
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760596/
https://www.ncbi.nlm.nih.gov/pubmed/33260766
http://dx.doi.org/10.3390/diagnostics10121021
_version_ 1783627369772220416
author Holm, Jorun
Ahangarani Farahani, Ziba
Gerke, Oke
Baun, Christina
Falch, Kirsten
Malene Grubbe, Hildebrandt
author_facet Holm, Jorun
Ahangarani Farahani, Ziba
Gerke, Oke
Baun, Christina
Falch, Kirsten
Malene Grubbe, Hildebrandt
author_sort Holm, Jorun
collection PubMed
description The purpose was to investigate the interrater agreement of FDG-PET/CT and bone scintigraphy for diagnosing bone recurrence in breast cancer patients. A total of 100 women with suspected recurrence of breast cancer underwent planar whole-body bone scintigraphy with [99mTc]DPD and FDG-PET/CT. Scans were evaluated independently by experienced nuclear medicine physicians and the results for one modality were blinded to the other. Images were visually interpreted using a 4-point assessment scale (0 = no metastases, 1 = probably no metastases, 2 = probably metastases, 3 = definite metastases). Out of 100 women, 22 (22%) were verified with distant recurrence, 18 of these had bone involvement. The proportions of agreement between readers were 93% (86.3–96.6) for bone recurrence with FDG-PET/CT and 47% (37.5–56.7) for bone recurrence with planar bone scintigraphy. The strengths of agreement between readers for diagnosing bone recurrence was ‘almost perfect’ with FDG-PET/CT and was ‘fair’ with planar bone scintigraphy according to Cohen’s kappa value of 0.82 (0.70–0.95) and 0.28 (0.18–0.39), respectively. Interrater agreement yielded improved reproducibility with FDG-PET/CT versus with bone scintigraphy when diagnosing recurrence with bone metastasis in this patient cohort.
format Online
Article
Text
id pubmed-7760596
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77605962020-12-26 Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer Holm, Jorun Ahangarani Farahani, Ziba Gerke, Oke Baun, Christina Falch, Kirsten Malene Grubbe, Hildebrandt Diagnostics (Basel) Article The purpose was to investigate the interrater agreement of FDG-PET/CT and bone scintigraphy for diagnosing bone recurrence in breast cancer patients. A total of 100 women with suspected recurrence of breast cancer underwent planar whole-body bone scintigraphy with [99mTc]DPD and FDG-PET/CT. Scans were evaluated independently by experienced nuclear medicine physicians and the results for one modality were blinded to the other. Images were visually interpreted using a 4-point assessment scale (0 = no metastases, 1 = probably no metastases, 2 = probably metastases, 3 = definite metastases). Out of 100 women, 22 (22%) were verified with distant recurrence, 18 of these had bone involvement. The proportions of agreement between readers were 93% (86.3–96.6) for bone recurrence with FDG-PET/CT and 47% (37.5–56.7) for bone recurrence with planar bone scintigraphy. The strengths of agreement between readers for diagnosing bone recurrence was ‘almost perfect’ with FDG-PET/CT and was ‘fair’ with planar bone scintigraphy according to Cohen’s kappa value of 0.82 (0.70–0.95) and 0.28 (0.18–0.39), respectively. Interrater agreement yielded improved reproducibility with FDG-PET/CT versus with bone scintigraphy when diagnosing recurrence with bone metastasis in this patient cohort. MDPI 2020-11-28 /pmc/articles/PMC7760596/ /pubmed/33260766 http://dx.doi.org/10.3390/diagnostics10121021 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Holm, Jorun
Ahangarani Farahani, Ziba
Gerke, Oke
Baun, Christina
Falch, Kirsten
Malene Grubbe, Hildebrandt
Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
title Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
title_full Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
title_fullStr Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
title_full_unstemmed Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
title_short Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer
title_sort higher interrater agreement of fdg-pet/ct than bone scintigraphy in diagnosing bone recurrent breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760596/
https://www.ncbi.nlm.nih.gov/pubmed/33260766
http://dx.doi.org/10.3390/diagnostics10121021
work_keys_str_mv AT holmjorun higherinterrateragreementoffdgpetctthanbonescintigraphyindiagnosingbonerecurrentbreastcancer
AT ahangaranifarahaniziba higherinterrateragreementoffdgpetctthanbonescintigraphyindiagnosingbonerecurrentbreastcancer
AT gerkeoke higherinterrateragreementoffdgpetctthanbonescintigraphyindiagnosingbonerecurrentbreastcancer
AT baunchristina higherinterrateragreementoffdgpetctthanbonescintigraphyindiagnosingbonerecurrentbreastcancer
AT falchkirsten higherinterrateragreementoffdgpetctthanbonescintigraphyindiagnosingbonerecurrentbreastcancer
AT malenegrubbehildebrandt higherinterrateragreementoffdgpetctthanbonescintigraphyindiagnosingbonerecurrentbreastcancer